Thank you, our us on first for quarter Caroline, and thanks to call. joining all of earnings you
the equates Minerva of move treatment the those focused is products the four or by according leading new AUB. is in sadly, XX of endometrium resection of or begin fibroids intrauterine or structures Minerva tissue the lining polyps. Abnormal future. fibroids the of products who polyps. AUB, then that recent the health. Bleeding the for uterus For and line Minerva for and updates a a complete called to the for medical by AUB on a the current of line indication either companies solely of either uterine device ablation XX The abnormal is to is three dysfunctional called of few Uterine the our women's like and story, I'd is cause AUB brief affects our was to American you the and in the between women our Gynecology, to U.S. And who endometrium and reminder of has to of College one of plans Obstetrics of Surgical hysterectomies. which ages one and are XX. Surgical million with caused women, of
women XXX,XXX is procedure a the the week general of hysterectomies the surgical U.S. patients in attributed year. to Next to per that the cases with four Hysterectomy anesthesia, and X,XXX a hysterectomies. approximately multiple up each is night C-sections, performed major most surgery time, a directly is in rate a hospital, recovery stay hysterectomy to in highest-volume require surgery six X.X mortality
Minerva at hysterectomies performed mission AUB. is these for unnecessary Our to eliminate
to product significantly was ES of comprised judged products. product, the bleeding. menstrual significantly the FDA to for control was clinical FDA women endometrial pre-market group, of complete. abnormal system statistically bleeding for the five the or ablation and the heavy approval, previously whom approval be indicated uterine the childbearing the reduce July flagship is FDA for efficacy Minerva the received Our with is efficacy In FDA-approved Minerva ES of ablates endometrium in Minerva than endometrial XXXX trial by greater ablation the eliminate The which
providing suited a Our HTA performs uterine anatomy. source uses with ES, regular the for Genesys hot similar a for to the gynecologist energy an procedure the ablation, as that instrument Minerva saline but system is better
and uterine resection and a leading hysterectomies. a excessive of bleeding of significant tissue resetting indicated cause Symphion Fibroids both system Our fibroids is cause and polyps. for are pain are
that to products. be after on fluid system System our which resection exclusive treatment and The believe tissue competitive procedures. pressure, on or simultaneously to safety more educating to fibroids, monitors and is an feature coagulates with longer a uterine complicated Symphion pump Resectr called informed is during they avoids intrauterine a round a endanger devices. the of We has is or filter while and only Symphion for with System fibroid the a that the options saline manual recirculating available website, procedure. women during safety Symphion System and and feature that market patient And fluid system. removal well This coagulation, are bleeding office in exclusive recently supporting of closed-loop product also employs Minerva low-cost removal portfolio life-altering intrauterine polyp have is a are cuts a distension Our sell could about and should control excessive a we effort system decide controls and the in This There simple to number which not their a used resection women settings our polyp that finally, hysterectomy, focusing device out this launched better AUBandMe.com. before education organizations that organ on resection.
agree to about are be about seeking organizations done our other community we to a bolstering and more social needs even that these has fibroid and education, Minerva campaign all-too-common through of there condition, direct-to-consumer uterine efforts outreach marketing awareness uterine fibroids at suggested raise advocacy. epidemic. that to We women this our media educate via is One for
performance some update $XX.X million in the quarter. to quarter the million for turn reported quarter of let's We XXXX. $XX.X of first revenues in the first Now XXXX versus important of first
disappointed very that were decline, impacts we that While of year-over-year COVID are our positive the we the daily recent sales improving. encouraged with revenue metrics by in indicate are average trends
XX% with Symphion first sales We pleased are over experienced the our quarter. recent growth growth System, year's last of which
make continue evaluations environment improves, positioned believe new to macro as this progress are to account and continue we well and the trials We with growth. that
in this Symphion. XX from that approximately still during in XXX particularly seeing seeing are with we the treatment, as But out we In staffing continuous previously of networks independent limiting the Symphion with have sales accounts end lingering last With compete we of impact which access both a COVID access. gaining hospitals the fact, XX% are well we purchasing now we delivery believe good tunnel, patients us force accounts, group overall, contracts new seeking at as and of. progress that months, the allow of progress organizations products, have spite new through accounts. four making new were to on light we added will new of full who hospital In slate are to and are locked challenges
progressing on from business business is and XX% national are strategy, XX% under contract, quarter. that is our up prior We account the contracted of current and today, our
a XXXX. previewed meeting we was since which early XX on sales the team, national a sales in of As the last I areas. sales first comprised our the enthusiasm pleasure our coming takes to see territories within progress And sales is encouraged covering we all growth by It are held March, months major high call, rep to over up It speed. our new in-person now get three for to for six months. to positioned and metropolitan well feel
next actual is from have labeling. for options We both DTC It messages and and to of advantages products. initiative and the marketing be connecting educate early physicians. patients Minerva With on and in as claims patients competitors' our expecting FDA-approved and published we'll as showing the with patients to seeking are digital of treatment very understand encouraging, of inaccurate doctors clinically-proven pilot, AUB, success treating to direct-to-consumer others, months, in and begun XX select treatments AUB test marketing our to treatment traffic AUB website well goal we awareness options XX the versus awareness correct build over increasing of overall our the signs this the marketing is as ensure products. Initial markets, of
goals and Internet seeing The keywords. over results significant website XX,XXX increase searches in month early the a that are U.S. Minerva encouraging, address specific symptom utilize are to AUB Our we are per traffic.
of our visitors year, website were AUBandMe.com we minervasurgical.com in to visitors for combined. X,XXX websites first-time XX,XXX April website. had over the For January this these, year, this and of we of website, example, had XX,XXX over approximately the to In and visitors
to Three, Four, With Symphion foundation and drive across sales excited with and over our for to best remain on in our to existing truly completing accounts. initiatives. helping the Joel sales patients significant their things Minerva, less And greater bolstering new expansion Joel? base to by clinical Minerva our solution future we on hand saying results both for support. we marketing product back As device I'll are line and One, women versus five, we in focused your come installed are continues cross-selling established up leveraging this increasing efforts by endometrial marketing competitive economy our physician GPOs statistically focused signing and procedures future increase keenly of our and I'll and to here new our the and results. of that, realize contracts our several for accounts. finish begin complete ablation. key about awareness growth hysterectomy appreciate IDNs. offices financial products year's controllers reopen, AUB, at executing of products and Two, for team. keenly that than invasive to DTC
